vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and Dayforce (DAY). Click either name above to swap in a different company.
Dayforce is the larger business by last-quarter revenue ($481.6M vs $247.1M, roughly 1.9× ANI PHARMACEUTICALS INC). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs -40.9%, a 52.0% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 9.5%). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 9.8%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Dayforce, Inc., formerly Ceridian, is an American human resources software and services company.
ANIP vs DAY — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $481.6M |
| Net Profit | $27.5M | $-196.8M |
| Gross Margin | — | — |
| Operating Margin | 14.1% | 6.3% |
| Net Margin | 11.1% | -40.9% |
| Revenue YoY | 29.6% | 9.5% |
| Net Profit YoY | 367.5% | -9940.0% |
| EPS (diluted) | $1.14 | $-1.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | — | ||
| Q3 25 | $227.8M | $481.6M | ||
| Q2 25 | $211.4M | $464.7M | ||
| Q1 25 | $197.1M | $481.8M | ||
| Q4 24 | $190.6M | $465.2M | ||
| Q3 24 | $148.3M | $440.0M | ||
| Q2 24 | $138.0M | $423.3M | ||
| Q1 24 | $137.4M | $431.5M |
| Q4 25 | $27.5M | — | ||
| Q3 25 | $26.6M | $-196.8M | ||
| Q2 25 | $8.5M | $21.3M | ||
| Q1 25 | $15.7M | $14.9M | ||
| Q4 24 | $-10.3M | $10.8M | ||
| Q3 24 | $-24.2M | $2.0M | ||
| Q2 24 | $-2.3M | $-1.8M | ||
| Q1 24 | $18.2M | $7.1M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 47.0% | ||
| Q3 24 | — | 45.8% | ||
| Q2 24 | — | 44.1% | ||
| Q1 24 | — | 47.6% |
| Q4 25 | 14.1% | — | ||
| Q3 25 | 15.9% | 6.3% | ||
| Q2 25 | 6.6% | 9.1% | ||
| Q1 25 | 13.3% | 6.4% | ||
| Q4 24 | -2.3% | 6.1% | ||
| Q3 24 | -13.8% | 4.7% | ||
| Q2 24 | 3.7% | 3.3% | ||
| Q1 24 | 14.8% | 9.4% |
| Q4 25 | 11.1% | — | ||
| Q3 25 | 11.7% | -40.9% | ||
| Q2 25 | 4.0% | 4.6% | ||
| Q1 25 | 8.0% | 3.1% | ||
| Q4 24 | -5.4% | 2.3% | ||
| Q3 24 | -16.3% | 0.5% | ||
| Q2 24 | -1.7% | -0.4% | ||
| Q1 24 | 13.2% | 1.6% |
| Q4 25 | $1.14 | — | ||
| Q3 25 | $1.13 | $-1.23 | ||
| Q2 25 | $0.36 | $0.13 | ||
| Q1 25 | $0.69 | $0.09 | ||
| Q4 24 | $-0.45 | $0.07 | ||
| Q3 24 | $-1.27 | $0.01 | ||
| Q2 24 | $-0.14 | $-0.01 | ||
| Q1 24 | $0.82 | $0.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $627.6M |
| Total DebtLower is stronger | — | $631.1M |
| Stockholders' EquityBook value | $540.7M | $2.7B |
| Total Assets | $1.4B | $8.7B |
| Debt / EquityLower = less leverage | — | 0.23× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | — | ||
| Q3 25 | $262.6M | $627.6M | ||
| Q2 25 | $217.8M | $625.2M | ||
| Q1 25 | $149.8M | $557.3M | ||
| Q4 24 | $144.9M | $579.7M | ||
| Q3 24 | $145.0M | $494.1M | ||
| Q2 24 | $240.1M | $465.4M | ||
| Q1 24 | $228.6M | $392.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | $631.1M | ||
| Q2 25 | — | $631.8M | ||
| Q1 25 | — | $632.4M | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $1.2B | ||
| Q1 24 | — | $1.2B |
| Q4 25 | $540.7M | — | ||
| Q3 25 | $505.8M | $2.7B | ||
| Q2 25 | $436.8M | $2.7B | ||
| Q1 25 | $418.6M | $2.6B | ||
| Q4 24 | $403.7M | $2.5B | ||
| Q3 24 | $405.9M | $2.6B | ||
| Q2 24 | $455.8M | $2.5B | ||
| Q1 24 | $452.0M | $2.4B |
| Q4 25 | $1.4B | — | ||
| Q3 25 | $1.4B | $8.7B | ||
| Q2 25 | $1.3B | $8.5B | ||
| Q1 25 | $1.3B | $9.5B | ||
| Q4 24 | $1.3B | $9.1B | ||
| Q3 24 | $1.3B | $8.1B | ||
| Q2 24 | $920.8M | $9.0B | ||
| Q1 24 | $914.5M | $10.8B |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.23× | ||
| Q2 25 | — | 0.23× | ||
| Q1 25 | — | 0.24× | ||
| Q4 24 | — | 0.47× | ||
| Q3 24 | — | 0.47× | ||
| Q2 24 | — | 0.49× | ||
| Q1 24 | — | 0.50× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $31.2M |
| Free Cash FlowOCF − Capex | $29.1M | — |
| FCF MarginFCF / Revenue | 11.8% | — |
| Capex IntensityCapex / Revenue | 0.5% | — |
| Cash ConversionOCF / Net Profit | 1.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | — | ||
| Q3 25 | $44.1M | $31.2M | ||
| Q2 25 | $75.8M | $112.7M | ||
| Q1 25 | $35.0M | $49.6M | ||
| Q4 24 | $15.9M | $81.0M | ||
| Q3 24 | $12.5M | $91.8M | ||
| Q2 24 | $17.4M | $99.2M | ||
| Q1 24 | $18.3M | $9.1M |
| Q4 25 | $29.1M | — | ||
| Q3 25 | $38.0M | — | ||
| Q2 25 | $71.8M | — | ||
| Q1 25 | $32.5M | — | ||
| Q4 24 | $13.5M | — | ||
| Q3 24 | $7.7M | — | ||
| Q2 24 | $13.0M | — | ||
| Q1 24 | $13.7M | — |
| Q4 25 | 11.8% | — | ||
| Q3 25 | 16.7% | — | ||
| Q2 25 | 34.0% | — | ||
| Q1 25 | 16.5% | — | ||
| Q4 24 | 7.1% | — | ||
| Q3 24 | 5.2% | — | ||
| Q2 24 | 9.4% | — | ||
| Q1 24 | 10.0% | — |
| Q4 25 | 0.5% | — | ||
| Q3 25 | 2.7% | — | ||
| Q2 25 | 1.9% | — | ||
| Q1 25 | 1.3% | — | ||
| Q4 24 | 1.3% | — | ||
| Q3 24 | 3.2% | — | ||
| Q2 24 | 3.2% | — | ||
| Q1 24 | 3.3% | — |
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 8.87× | 5.29× | ||
| Q1 25 | 2.23× | 3.33× | ||
| Q4 24 | — | 7.50× | ||
| Q3 24 | — | 45.90× | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.00× | 1.28× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
DAY
| Dayforce Recurring | $333.0M | 69% |
| Cloud And Bureau Professional Services And Other | $78.5M | 16% |
| Float | $42.2M | 9% |
| Powerpay Recurring | $19.7M | 4% |
| Other Recurring | $8.2M | 2% |
